Skip to main content
UK clinical trials - updated daily from ClinicalTrials.gov
TrialConnect
← Back to Search
Looking for participantsNA

Liquid Biopsy System Intracoronary Blood Sampling and Analysis to Characterise Disease Biomarkers in Patients With Coronary Disease

Sponsor: PlaqueTec Ltd

NCT ID: NCT06259019

View on ClinicalTrials.gov ↗

At a glance

What the study gets you
Access to the study treatment being tested
Type of study
Interventional (receives a drug or procedure)
Time in hospital
In-person visits at study sites — visit count not specified by the sponsor
Drug or intervention
Liquid Biopsy System (LBS) (device)
How long the study runs
Study runs about 53 months (dates as stated)
About the drug or intervention
Liquid Biopsy System (LBS) — device: Coronary artery catheter designed to mix intra-arterial flow and simultaneously extract multiple blood samples from around the site of coronary disease within a vessel of interest.
Patient visit burden
Not specified by the sponsor
Type of study
Testing a treatment
Ages
18 Years and over
Who
All
Number of participants
300
Started
2023-09-14
Last checked
2026-03

Plain English Summary

What is this study?

  • • Testing a new treatment for coronary artery disease
  • • NA - 300 participants
  • • The aim of this research, proposed and funded by PlaqueTec and co-ordinated by Papworth Trials Unit Collaboration, is to demonstrate the performance of the coronary artery blood sampling device (Liquid Biospy System, LBS) and establish its usefulness to collect a range of disease biomolecules from the coronary artery of interest

Who can take part?

  • • Ages 18 Years and over
  • • Diagnosed with coronary artery disease

Where?

  • • Bournemouth - Royal Bournemouth Hospital
  • • Bristol - Bristol Heart Institute
  • • Cambridge - Royal Papworth Hospital
  • • Norwich - Norfolk and Norwich Hospital

This is a simplified summary. Always discuss with your doctor before making any decisions.

About This Trial

The aim of this research, proposed and funded by PlaqueTec and co-ordinated by Papworth Trials Unit Collaboration, is to demonstrate the performance of the coronary artery blood sampling device (Liquid Biospy System, LBS) and establish its usefulness to collect a range of disease biomolecules from the coronary artery of interest. Using the data generated from extensive analysis of the blood samples, key biomarker data will be generated that will close a knowledge gap and facilitate the development of tailored treatments for coronary artery disease.

Coronary Artery Disease

How this trial compares with your answers

Answer 2 more questions to improve match

What we know so far

Condition· Matched your search
Age· Tell us your age for better matching
Gender· Tell us your sex for better matching

Still need:

  • • Tell us your age for better matching
  • • Tell us your sex for better matching

Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.

Eligibility at a Glance

Key info

  • Age: 18 Years and over
  • Who can join: All genders

Biomarkers mentioned

Troponin negativeeGFR

What the study is looking for

  • ✓Stage 1 screening inclusion:
  • ✓≥18 years of age, have capacity and be willing to provide agreement to take part to participate
  • ✓Clinical evidence of obstructive coronary artery disease and be scheduled for either:
  • ✓Elective coronary angiography +/- proceed for stable angina OR
  • ✓Elective PCI for stable angina with known bystander disease OR

Who cannot take part

  • ✗Stage 1 screening exclusion:
  • ✗Myocardial Infarction within 30 days of procedure.
  • ✗Chronic kidney failure (eGFR\<30ml/min/1.73m2).
  • ✗Contrast allergy.
  • ✗Hypotension, shock or haemodynamic instability.
See the full criteria
Inclusion Criteria: Stage 1 screening inclusion: 1. ≥18 years of age, have capacity and be willing to provide informed consent to participate 2. Clinical evidence of obstructive coronary artery disease and be scheduled for either: 1. Elective coronary angiography +/- proceed for stable angina OR 2. Elective PCI for stable angina with known bystander disease OR 3. Angiography +/- proceed for Troponin negative unstable angina Stage 2 screening inclusion: Suitable lesion identified meeting angiographic criteria for LBS deployment and Cardiologist comfortable to deploy OCT and LBS on study lesion before carrying out PCI on any lesion Exclusion Criteria: Stage 1 screening exclusion: 1. Myocardial Infarction within 30 days of procedure. 2. Chronic renal failure (eGFR\<30ml/min/1.73m2). 3. Contrast allergy. 4. Hypotension, shock or haemodynamic instability. 5. Ventricular arrhythmia. 6. Chronic Heart Failure (NYHA ≥ 3) or LVEF ≤ 30%. 7. Immunocompromised or receiving immunosuppressant therapy. 8. Any active disease that in the opinion of the investigator makes the subject unsuitable for the research procedure or subject life expectancy less than 1 year. 9. Active infection or sepsis (significant CRP elevation and/or requiring antibiotics). 10. Active systemic inflammatory condition. 11. Inability to receive anticoagulants or antiplatelets or uncorrected bleeding disorder or deranged platelet count. 12. Is pregnant. 13. Deemed high clinical risk or unsuitable for the procedure for any reason by the treating clinician. Stage 2 screening exclusion: 1. Target lesion is in the left main coronary artery. 2. Unsuitable coronary anatomy (vessel tortuosity \[\>45 degree bend\], moderate/ severe calcification angiographically, ostial disease). 3. Presence of thrombus in the target vessel. 4. Prior PCI or stent or graft in vessel identified for LBS sampling. 5. No clinical indication for either a PCI or a pressure wire assessment on any lesion.

Where Is This Study? (4 UK sites)

Royal Bournemouth Hospital

Bournemouth, United Kingdom

Recruiting
Site contact (verified)
Principal Investigatorpeter.o'kane@uhd.nhs.uk

Bristol Heart Institute

Bristol, United Kingdom

Recruiting
Site contact (verified)
Principal Investigatortom.johnson@uhbw.nhs.uk

Royal Papworth Hospital

Cambridge, United Kingdom

Recruiting
Site contact (verified)
Principal Investigatorsteve.hoole@nhs.net

Norfolk and Norwich Hospital

Norwich, United Kingdom

Recruiting
Site contact (verified)
Principal Investigatoralisdair.ryding@nnuh.nhs.uk

How to Get in Touch

Clinical Project Manager

Sponsor contact

CONTACT

01223638000 papworth.biopattern@nhs.net

PlaqueTec General Manager

Sponsor contact

CONTACT

simon@plaquetec.com
Data sourced from ClinicalTrials.gov · Last verified: 2026-03